Target
Fibroblast growth factor receptor 2
Ligand
BDBM262076
Substrate
n/a
Meas. Tech.
FGFR Enzymatic Assay 2
IC50
<10±n/a nM
Citation
 Lu, LShen, BSokolsky, AWang, XWu, LYao, WYe, Y Bicyclic heterocycles as FGFR4 inhibitors US Patent  US9708318 Publication Date 7/18/2017 
Target
Name:
Fibroblast growth factor receptor 2
Synonyms:
BEK | CD_antigen=CD332 | FGFR-2 | FGFR-2 Tyrosine Kinase | FGFR2 | FGFR2_HUMAN | Fibroblast growth factor receptor 2 (FGFR2) | Fibroblast growth factor receptor 2 precursor | KGFR | KSAM | Keratinocyte growth factor receptor | Keratinocyte growth factor receptor 2 | VEGF-receptor 2 and Fibroblast growth factor receptor 2
Type:
Enzyme
Mol. Mass.:
92015.45
Organism:
Homo sapiens (Human)
Description:
P21802
Residue:
821
Sequence:
MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEVRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYFMVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVLPAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTKRIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDKLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTFKDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYSPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT
  
Inhibitor
Name:
BDBM262076
Synonyms:
3-(2,6-difluoro-3,5- dimethoxyphenyl)-7-(1,3- dimethyl-1H-pyrazol-4-yl)-1- ((2-methylpyrimidin-4- yl)methyl)-3,4- dihydropyrido[4,3-d]pyrimidin- 2(1H)-one | US10251892, Example 121 | US11173162, Example 121 | US9708318, 121
Type:
Small organic molecule
Emp. Form.:
C26H25F2N7O3
Mol. Mass.:
521.5186
SMILES:
COc1cc(OC)c(F)c(N2Cc3cnc(cc3N(Cc3ccnc(C)n3)C2=O)-c2cn(C)nc2C)c1F
Structure:
Search PDB for entries with ligand similarity: